Lale Tokgozoglu; David A. Morrow; Stephen J. Nicholls Eur Heart J. 2023;44(25):2292-2304. Advantages of tailoring lipid lowering therapy with biomarkers versus imaging. Dyslipidemia is an important modifiable risk factor for atherosclerotic cardiovascular disease (ASCVD) and lipid lowering an integral component of cardiovascular prevention. Apolipoprotein B containing lipoproteins—mainly low-density lipoprotein cholesterol (LDL-C)—have indubitably been shown to be...